Monoamine oxidase inhibitors are among the combinations the interaction literature treats most cautiously, for a clear mechanistic reason: they engage psilocin through two compounding routes at once. Psilocin is partly cleared by monoamine oxidase, so inhibiting that enzyme is expected to raise and prolong psilocin exposure — a pharmacokinetic effect demonstrated dramatically in ayahuasca, where an MAOI makes an otherwise orally inactive tryptamine active. MAOIs also raise serotonin broadly, so adding a serotonergic psychedelic increases total serotonergic load, the setting in which serotonin syndrome arises. Both mechanisms are well grounded; what is missing is any measurement of their magnitude at microdose levels. The result is a high-caution verdict built on solid pharmacology rather than counted incidents. This is not medical advice. Anyone taking an MAOI should treat the combination as requiring a clinician’s involvement and must never stop a prescribed MAOI on their own.
This is an evidence review, not medication guidance. Whether an interaction matters depends on dose, diagnosis, medication history, timing, and individual vulnerability. Nothing here should be used to start, stop, combine, or adjust a prescribed medication — those decisions belong with the clinician who prescribed it.
Why MAOIs are the cleaner danger to reason about
Unlike most entries in this cluster, the MAOI interaction does not depend on disputed survey data. It follows from how psilocin is handled by the body, and that pharmacology is reasonably well characterized. Psilocybin itself is a prodrug; after ingestion it is rapidly converted to psilocin, the active molecule. Psilocin is then cleared by two main routes — glucuronidation, and oxidative breakdown by monoamine oxidase. [1] Peer-reviewed Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance doi:10.1080/03602532.2016.1278228 Monoamine oxidase is exactly the enzyme an MAOI inhibits.
The pharmacokinetic prediction is therefore straightforward. Inhibit the enzyme that helps clear psilocin, and psilocin clears more slowly: higher peak levels, longer duration, more total exposure from the same dose. The metabolism behind this is set out in how psilocybin becomes psilocin. This is not a fringe hypothesis — it is the same principle that makes ayahuasca work, where a plant MAOI is deliberately combined with the tryptamine DMT to render an orally inactive compound active. For psilocin, the same logic predicts amplification: a dose meant to be sub-perceptual may not stay that way.
The second mechanism stacked on the first
If amplified exposure were the only concern, MAOIs would sit alongside other pharmacokinetic interactions. What raises them to high-caution status is a second, pharmacodynamic mechanism operating at the same time. MAOIs raise serotonin levels throughout the system by preventing its breakdown. Adding a serotonergic psychedelic — psilocin acts on serotonin receptors, principally 5-HT2A — increases total serotonergic activity further. [2] Peer-reviewed Psychedelics doi:10.1124/pr.115.011478 Excessive serotonergic activity is the definition of serotonin syndrome, a potentially life-threatening reaction that classically arises when serotonergic drugs are combined, with MAOIs among the agents most often implicated. [3] Peer-reviewed The serotonin syndrome doi:10.1056/NEJMra041867
So the MAOI case is two compounding mechanisms: more active drug, in a system already pushed toward serotonergic excess. Either alone would warrant caution; together they are why MAOIs are consistently flagged above SSRIs.
| Mechanism | Type | Predicted effect | Evidence status |
|---|---|---|---|
| MAO inhibition slows psilocin clearance | Pharmacokinetic | Higher, longer psilocin exposure | Well grounded in metabolism; ayahuasca demonstrates the principle |
| MAOI raises systemic serotonin | Pharmacodynamic | Greater total serotonergic load | Established mechanism; basis of serotonin syndrome risk |
| Net effect at microdose levels | Combined | Plausibly amplified and riskier | Not measured — no microdose incidence data |
What the evidence does and doesn’t say
The mechanisms are sound; the human data on this specific combination are not extensive. The systematic review of psychiatric-drug interactions with psilocybin found the overall evidence base small, and the MAOI material rests more on pharmacological reasoning and analogy to related tryptamines than on a body of controlled human studies of psilocybin plus an MAOI. [4] Systematic review Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review doi:10.1007/s00213-022-06083-y That distinction matters for how the caution should be read: it is a strong mechanistic caution, not a measured probability of a bad outcome at any particular dose.
One more distinction keeps “MAOI” from being treated as a single thing. Irreversible prescription MAOIs (such as phenelzine or tranylcypromine), reversible MAO-A inhibitors, MAO-B–selective agents, plant-derived MAOIs like the harmala alkaloids in ayahuasca brews, and the weak MAO activity found in some foods are not interchangeable. They differ in potency, in whether the inhibition is reversible, in how long it persists after the last dose, and in how serotonin-specific it is — and the resulting interaction risk tracks those properties rather than the word “MAOI” alone. The practical implication is not a ranking to act on, but that no single rule covers the category, which is another reason it belongs with a clinician.
Crucially, none of the reasoning is microdose-specific. A microdose is sub-perceptual by definition, and it is conceivable that the amplification an MAOI produces is modest at very low doses — but it is equally conceivable that MAOI-driven amplification is precisely what converts a sub-perceptual dose into a perceptual one. With no measurement either way, and with serotonin syndrome as the downside, the literature’s posture is caution rather than reassurance.
- Psilocin is cleared by monoamine oxidase
- Psilocin’s breakdown depends partly on the enzyme MAOIs inhibit, so an MAOI is expected to raise and prolong psilocin exposure. [1] Peer-reviewed Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance doi:10.1080/03602532.2016.1278228
- The ayahuasca principle
- Combining an MAOI with a tryptamine can make an otherwise inactive compound active — direct proof that MAO inhibition amplifies tryptamine effects. [1] Peer-reviewed Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance doi:10.1080/03602532.2016.1278228
- Compounding serotonergic load
- MAOIs raise systemic serotonin; adding a serotonergic psychedelic increases total activity, the mechanism behind serotonin syndrome. [3] Peer-reviewed The serotonin syndrome doi:10.1056/NEJMra041867
- Strong mechanism, no microdose incidence
- The MAOI caution rests on well-grounded pharmacology, not on counted harms at microdose levels. [4] Systematic review Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review doi:10.1007/s00213-022-06083-y
Frequently asked questions
Is it safe to microdose while taking an MAOI?
This is one of the combinations the literature treats with the most caution, and the responsible answer is that it should not be approached without medical supervision. MAOIs inhibit the enzyme that helps clear psilocin, which can raise and prolong psilocin exposure, [1] Peer-reviewed Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance doi:10.1080/03602532.2016.1278228 and they raise overall serotonergic load, the setting in which serotonin syndrome becomes a concern. [3] Peer-reviewed The serotonin syndrome doi:10.1056/NEJMra041867 The exact magnitude at microdose levels has not been measured, so the caution is mechanistic and clinical rather than a counted incidence. [4] Systematic review Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review doi:10.1007/s00213-022-06083-y This is not medical advice; anyone taking an MAOI should treat the combination as one requiring a clinician’s involvement and should never stop a prescribed MAOI on their own.
Do MAOIs make psilocybin stronger?
Mechanistically, that is the expectation, and it is well established for related tryptamines. Psilocin is partly broken down by monoamine oxidase, so inhibiting that enzyme should slow its clearance and increase how much active drug circulates and for how long. [1] Peer-reviewed Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance doi:10.1080/03602532.2016.1278228 The clearest real-world demonstration is ayahuasca, where an MAOI is combined with the tryptamine DMT specifically to make an otherwise orally inactive compound active. For psilocin the same logic predicts amplification, but the precise effect at microdose levels in humans has not been characterized.
What is the actual danger with MAOIs and psilocybin?
Two concerns sit on top of each other. The first is pharmacokinetic: raised and prolonged psilocin exposure means a dose intended to be sub-perceptual may not stay sub-perceptual. [1] Peer-reviewed Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance doi:10.1080/03602532.2016.1278228 The second is pharmacodynamic: MAOIs raise serotonin levels broadly, and adding a serotonergic psychedelic increases total serotonergic activity, the mechanism behind serotonin syndrome. [3] Peer-reviewed The serotonin syndrome doi:10.1056/NEJMra041867 Whether either reaches a dangerous threshold at a true microdose is not documented, but the combination of two compounding mechanisms is why MAOIs are flagged for higher caution than SSRIs.
Are dietary MAOIs like those in some plants a concern too?
The interaction is a property of monoamine oxidase inhibition itself, so in principle any sufficiently active MAOI engages the same mechanism, which is precisely how ayahuasca brews work. [1] Peer-reviewed Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance doi:10.1080/03602532.2016.1278228 That said, the strength and reliability of inhibition varies enormously, and most casual dietary exposures are not comparable to a therapeutic MAOI. The safe general rule the literature supports is that any genuine MAOI raises the caution level for combining with serotonergic compounds, and that this is a matter for a clinician rather than self-experimentation.
Should I stop or change my medication before microdosing?
No. Stopping, switching, or adjusting a prescribed medication carries its own serious risks — withdrawal, relapse, mood destabilization, or symptom rebound — independent of anything to do with psilocybin. Those decisions belong with the prescribing clinician who knows your history. This library describes what the research does and does not show; it is not a basis for changing treatment, and nothing here should be read as a reason to alter a prescribed medication on your own.